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antigens using a targeted protein microarray
approach
Hamish EG McWilliam1*, Patrick Driguez2, David Piedrafita3, Donald P McManus2 and Els NT Meeusen4Abstract
Background: Novel vaccine candidates against Schistosoma japonicum are required, and antigens present in the
vulnerable larval developmental stage are attractive targets. Post-genomic technologies are now available which
can contribute to such antigen discovery.
Methods: A schistosome-specific protein microarray was probed using the local antibody response against migrating
larvae. Antigens were assessed for their novelty and predicted larval expression and host-exposed features. One antigen
was further characterised and its sequence and structure were analysed in silico. Real-time polymerase chain reaction
was used to analyse transcript expression throughout development, and immunoblotting and enzyme-linked
immunosorbent assays employed to determine antigen recognition by antibody samples.
Results: Several known and novel antigens were discovered, two of which showed up-regulated transcription in
schistosomula. One novel antigen, termed S. japonicum Ly-6-like protein 1 (Sj-L6L-1), was further characterised and
shown to share structural and sequence features with the Ly-6 protein family. It was found to be present in the worm
tegument and expressed in both the larval and adult worms, but was found to be antigenic only in the lungs that the
larvae migrate to and traverse.
Conclusions: This study represents a novel approach to vaccine antigen discovery and may contribute to schistosome
vaccine development against this important group of human and veterinary pathogens.
Keywords: Schistosoma japonicum, Vaccine development, Ly-6 proteins, Protein microarray, ImmunomicsBackground
An effective vaccine against schistosomiasis would be a
major step towards eliminating this devastating and wide-
spread tropical parasitic disease, and has been the focus of
significant research effort for decades [1]. Numerous
schistosome vaccine candidates have been discovered
showing varying levels of protection, and several mole-
cules are in development [2]; however, a commercial vac-
cine still remains elusive. It has been suggested that more
effective vaccine candidates remain undiscovered, indica-
ting a need for novel approaches to target discovery [1,3].* Correspondence: hamish.mcwilliam@unimelb.edu.au
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article, unless otherwise stated.The radiation-attenuated larval vaccine model provides
evidence that high levels of protection can be generated
against schistosome infection. When a range of animal
models are infected with radiation-attenuated cercariae,
the resulting immunity rejects up to 90% of the challenge
infection [4,5]. In this model the larvae do not progress to
adult worms, and the consensus is that the early develo-
ping schistosomula represent a potent source of protective
antigens and are the target of this protective immune re-
sponse [4,5]. Furthermore, larval stages are also suspected
of being the target of naturally acquired immunity in
humans [6-8]. In contrast, the adult worms can live in the
host bloodstream for decades despite being surrounded by
specific components of the immune response [9,10].
Therefore larval-specific antigens, or molecules exposed
uniquely in larvae, have the potential to serve as effec-
tive novel vaccine candidates. Despite this, the currenttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and there is a lack of larval-specific antigens being eva-
luated [11].
Recently the genomes of all three major schistosome
species have been sequenced [12-14], and several post-
genomic approaches and high throughput methods have
been developed to take advantage of this wealth of infor-
mation [15]. One such approach is a schistosome-specific
protein microarray, which contains 232 unique antigens
displayed on nitrocellulose slides [16]. These proteins
were selected from bioinformatic data using criteria biased
towards promising vaccine candidates i.e. up-regulated
expression in larvae, predicted/known parasite surface
expression, and limited similarity with mammalian se-
quences [16]. Many of these are novel molecules and the
majority are from Schistosoma japonicum, with the re-
mainder from S. mansoni. The arrayed proteins can be
probed with antibodies from immune hosts as a powerful
new technology for vaccine antigen discovery [11].
In the present study, this protein microarray was
screened with antibodies generated from lymph nodes
draining the sites of larval S. japonicummigration [17]. Re-
ferred to as antibody secreting cell-probes (ASC-probes),
these antibodies are specific to the migrating skin and lung
larvae [17], and were generated from S. japonicum-in-
fected rats, which is a well-studied model of antibody-
mediated immunity against the migrating larvae during a
secondary infection [18-20]. Hence, these ASC-probes
have the potential to recognise protective larval antigens.
Using this approach we identified several novel antigens
expressed by schistosomula; one promising candidate was
further investigated indicating it may be an important tar-
get for vaccine development.
Methods
Ethics statement
The conducts and procedures involving animal experi-
ments were approved by the Monash University animal
ethics review board, and the Animals Ethics Committee
of the Queensland Institute of Medical Research (project
no. P288). This study was performed in accordance with
the recommendations of the Australian code of practice
for the care and use of animals for scientific purposes,
2004.
Protein microarray screening
A protein microarray consisting of 232 unique schisto-
some proteins was prepared as described by Driguez et al.
[16]. The microarray slides were hydrated using Blocking
Buffer (BB; Whatman) for 30–60 min at RT, using 16-pad
incubation chambers and frames (Whatman) to separate
arrays. Antibodies used for screening the microarrays were
obtained from lymph nodes of challenged rats as detailed
in McWilliam et al. [17]. Briefly, previously infected ratswere challenged with 350 cercariae and skin and lung
lymph nodes (LN) removed at 5 and 9 days after challenge
respectively. This protocol was designed based on pre-
vious observations that rats show antibody-mediated im-
munity against larvae during secondary infections [18,19].
LN cell suspensions were cultured in vitro for 5 days to
allow spontaneous secretion of antibodies by in vivo in-
duced antibody secreting cells (ASC) and the supernatant
collected and used as the antibody probe (=ASC-probe).
Considering ASC-probes from non-infected (NI) rats con-
tain little antibody [16], they are not ideal controls for
non-specific antibody binding; NI rat sera was therefore
used as the negative control. Four skin and four lung
ASC-probes (undiluted) or 15 NI serum samples (1:100 in
BB) were incubated on the arrays in a sealed box over-
night at 4°C. Skin and lung ASC-probes were selected
based on those containing the highest antibody concentra-
tion as documented in [16]. Arrays were washed 3 times
with tris-buffered saline (TBS; 20 mM tris, 150 mM NaCl)
with 0.05% Tween-20 (TBST), followed by biotin-conju-
gated anti-rat IgG (1:1000 in BB) for 1 h at RT. After 3
washes in TBST, streptavidin-conjugated Cy5 fluorophore
(Surelight P3, Columbia Biosciences; 1:200 in BB) was in-
cubated for 1 h at RT. After a final 3 washes in TBST the
array slides were separated from the chambers, washed in
distilled water and dried by centrifuging for 5 minutes at
500 × g. The slides were stored in the dark until scanned.
Microarray scanning and antigen identification
Scanning was performed on a confocal laser microarray
scanner (Genepix 4300A, Molecular Devices), and the sig-
nal intensity (SI) was quantified using image analysis soft-
ware (Genepix Pro 7, Molecular Devices) and transformed
and normalised using the vsn statistical package (http://
www.r-project.org). Finally the data were re-transformed
(inverse log2) to a normalised SI [21-23].
Antigens were considered positively recognised by an
ASC-probe sample when the SI was greater than two
standard deviations above the mean of NI rat sera. Amino
acid sequences of the identified antigens were then ana-
lysed for features of potentially important vaccine candi-
dates i.e. developmental expression based on EST Profile
Viewer (http://www.ncbi.nlm.nih.gov/ unigene), presence
of a signal peptide using SignalP −4.1 (www.cbs.dtu.dk/
services/SignalP), and a predicted transmembrane domain
with TMpred (www.ch.embnet.org/software/TMPRED_
form.html). Also, literature searches were performed to
determine the novelty of each antigen, which were con-
sidered novel when there were no reports of vaccine effi-
cacy against S. japonicum or significant characterisation.
RNA isolation from schistosome life-stages
Cercariae were obtained from freshly-shed infected Onco-
melania hupensis hupensis snails and transferred using a
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(Qiagen). Two-day (2d) schistosomula were manually
transformed from cercariae using the syringe method as
described in McWilliam et al. [17], and cultured in vitro
for 2 days at 37°C with 5% CO2. Three-day (3d) schis-
tosomula were obtained from infected mice lungs 3 days
post-infection (lung-stage schistosomula) as described by
Gobert et al. [24], and were lysed directly in Qiazol. Adult
worm pairs were obtained from freshly-perfused mice,
and either left as pairs or carefully separated, and washed
in PBS before homogenising in Qiazol. The RNA was then
extracted from each stage following the manufacturer’s
protocol and stored in water at −80°C until required.
Developmental expression of novel antigens by
quantitative real-time PCR (qPCR)
After determining the RNA concentration using a Nano-
Drop spectrophotometer (Thermo Scientific), total RNA
(300 ng) was converted to cDNA using the QuantiTect
Reverse Transcription Kit (Qiagen) including the genomic
DNA removal step. To perform the qPCR, primers were
designed based on the novel antigen sequences identified
in the protein microarray screening and using NADH
dehydrogenase ubiquinone flavoprotein 2 (NDUFV2) as
the reference gene [25]. The primer sequences were:
AY815838 (forward: 5′- CGTCGACATTCAAGTTGG
TC -3′, reverse: 5′- GGGGCATAATCTTCACTTTGA -3′);
Ly-6-like-1 (forward: 5′- TGAAAGTTTTGGGACTTTG
TATG -3′, reverse: 5′- CGAATGGATTCGGACAGT
CT -3′); calponin-like (forward: 5′- CATGTCATTCGGT
GCTCAAC -3′, reverse: 5′- TTCAGCAATATGACGTT
GATTACTA -3′) and NDUFV2 (forward: 5′- CGAG
GACCTAACAGCAGAGG -3′, reverse: 5′- TCCGAAC
GAACTTTGAATCC -3′). Because calponin-like protein
has homology to another calponin homologue in S. japo-
nicum (accession #AAD11976), the primers were designed
in the most dissimilar region. The qPCR reactions in-
cluded SYBR Master Mix (Applied Biosystems) and the
above primers at 0.5 μM and 5 μl of 1:20 diluted cDNA,
and were run in technical triplicates on an Eppendorf
Realplex4 Mastercycler for 35 cycles, using an annealing
temperature of 55°C. Melt curve analysis was performed
to ensure a single product was amplified. The relative
copy number of SYBR green for each gene was calculated
from a standard curve of serial dilutions of cDNA, and the
relative expression of the target gene was determined
relative to the reference gene copy number. Finally, the
expression of each gene was calculated relative to the cer-
carial cDNA level to observe the change throughout
development.
Sequence analysis of S. japonicum ly-6-like-1 (Sj-L6L-1)
The NCBI databases (http://blast.ncbi.nlm.nih.gov/Blast.
cgi) were used to identify Sj-L6L-1 related S. japonicum,S. mansoni, and mammalian species (Mus musculus and
Homo sapiens). For other parasitic trematodes (S. haemato-
bium, Fasciola hepatica, F. gigantica, Opisthorchis viverrini
and Clonorchis sinensis), searches were performed using the
databases at www.gasserlab.org. Sequence alignments were
performed by ClustalW2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). The presence of a signal peptide and omega site
(which denotes the position where the C-terminal pro-
peptide is cleaved off in the mature protein and is re-
placed with a glycosylphosphatidylinositol (GPI)-anchor)
was predicted by SignalP −4.1 (www.cbs.dtu.dk/services/
SignalP/) and big-PI predictor (http://mendel.imp.ac.at/
gpi/gpi_server.html), respectively. Structural homology
searches were performed using the amino acid sequence
of mature Sj-L6L-1 without the predicted N-terminal sig-
nal peptide and C-terminal propeptide (beginning at M20
and truncated at the predicted GPI-anchor attachment
site at N96) in the Phyre2 server (www.sbg.bio.ic.ac.uk/
phyre2) [26], and the protein structure was displayed
using PyMOL (v1.3; www.pymol.org).
Production and purification of recombinant Sj-L6L-1
(rSj-L6L-1)
The Sj-L6L-1 sequence was amplified from the pXi T7 vec-
tor used in the construction of the protein arrays [16].
Primers were designed to produce the mature Sj-L6L-1
protein (M20-N96) (forward primer: 5′-ATGAAAAA
TAAAAAGGTCAAATG-3′, reverse: 5′-ATTACAATAAT
CTTCATCACAAC-3′). Amplification of the 231 bp Sj-
L6L-1 fragment was performed using Phusion High Fidelity
DNA Polymerase (New England Biolabs). Next 3′ adenine
overhangs were added by incubating the PCR product with
1 unit of Platinum Taq DNA Polymerase (Life Technolo-
gies) and 0.2 mM dATP for 10 min at 72°C. This was puri-
fied and then cloned in-frame into the pBAD/TOPO
ThioFusion plasmid (Life Technologies) according to the
manufacturer’s directions. This resulted in a fusion protein
with thioredoxin (Escherichia coli) as a solubility tag and
6His purification tag at the amino- and carboxy- termini,
respectively.
The plasmid was sequenced to confirm the correct se-
quence, and then transformed into TOP10 E. coli cells
(Life Technologies). Expression was induced by adding
arabinose (0.005% w/v), and soluble rSj-L6L-1 present
in the bacterial lysate supernatant was purified on a
HisTrap HP column (GE Healthcare) according to the
manufacturer’s instructions. Fractions were analysed
by sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and the purest fraction was dia-
lysed into TBS (pH 8.0) and stored at −20°C. The
thioredoxin fusion partner alone (with the 6His tag; re-
ferred to as rTrx) was also produced using the ‘empty’
pBAD vector, and purified in the same way for use as a
control.
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by injecting a rat with 50 μg of rSj-L6L-1 or rTrx with
200 μg Quil A in 0.1 ml PBS. A secondary immunisation
was administered 2 weeks later, after which a test bleed
indicated a specific antibody response to the adminis-
tered antigen.
Schistosome protein extracts
Crude worm extracts were prepared by collecting each
developmental stage (as above), washing with TBS, and
homogenising in 1% (w/v) SDS in TBS. Samples were
centrifuged at 12,000 × g for 15 min at RT. The protein
concentration of the supernatants was determined by
BCA assay (Pierce, Rockford). To determine whether
Sj-L6L-1 was soluble and present in the tegument, adult
worms were separated into different fractions. Tegument
was gently removed by a modified freeze/thaw/vortex
technique [27,28]. Briefly, washed and snap-frozen worm
pairs were thawed in TBS (pH 7.5) on ice for 5 min,
followed by vortexing for 5 × 1 sec to allow gentle re-
moval of tegument. The supernatant was removed and
centrifuged at 13,000 × g for 10 min at 4°C. The tegu-
ment pellet was resuspended in lithium dodecyl sulphate
(LDS) sample buffer (Life Technologies) and heated to
95°C for 10 min. The remaining worms were washed in
20 mM Tris (pH 7.4) and then homogenised in the same
buffer. After centrifugation, as before, the supernatant
was kept as the soluble fraction. The pellet was washed
twice with buffer followed by another centrifugation
step, and then solubilised in 1% SDS. After spinning
again, the supernatant was kept as the aqueous-insoluble
fraction.
Western blotting for detection of native and recombinant
Sj-L6L-1
Purified rSj-L6L-1 or rTrx (1 μg) in LDS sample buffer
with or without reducing agent (50 mM dithiothreitol;
DTT), were run on 10% NuPAGE Bis-Tris gels, along with
Novex Sharp Pre-stained Protein Standards (Life Tech-
nologies) and stained with Coomassie blue. For western
blotting, rSj-L6L-1 (0.5 μg) or worm extracts (10 μg) were
separated by SDS-PAGE and transferred onto nitrocel-
lulose membranes, which were then blocked overnight at
4°C in 5% w/v skim milk powder in PBST (SM-PBST).
After washing three times in PBST, the primary antibodies
were added: rSj-L6L-1 was probed with neat pooled rat
lung-LN ASC-probes from infected rats; worm extracts
were probed with either anti-rSj-L6L-1 or anti-rTrx anti-
serum (1:500 in 1% SM-PBST). After washing, anti-rat Ig
(H + L):HRP (1:1000) (Life Technologies) was incubated
with the membranes for 1 h at RT, and the membranes re-
washed. Finally ECL substrate (GE Healthcare) was ap-
plied and chemiluminescence detected on Super RX film
(Fujifilm).Recognition of rSj-L6L-1 by enzyme-linked immunosorbant
assay (ELISA)
An ELISA was used to quantify the antigenicity of rSj-L6L-1
during schistosomiasis, using the ASC-probes and serum
samples from infected rats as described in McWilliam et al.
[17]. Some samples (particularly NI serum) showed binding
to the Trx fusion partner alone (data not shown); therefore
binding was measured to both rSj-L6L-1 and rTrx. Wells
were coated with recombinant protein (3 μg/ml) in car-
bonate coating buffer (pH 9.6) overnight at 4°C, and
blocked with 5% SM-PBST. The samples used for probing
consisted of NI rat serum at 1:200 (n = 3) or neat ASC-
probes from infected rat skin LN (n = 5); lung LN (n = 5);
liver LN (n = 5); and spleen (n = 4). Duplicate samples were
incubated in the wells for 2 h at 37°C. After washing anti-
rat Ig (H + L):HRP (1:5000) was incubated for 1 h at 37°C.
TMB solution (Life Technologies) was added to each well,
followed by 2 M H2SO4, and the optical density (OD) was
read at 450 nm. Statistical differences in binding of ASC-
probes to Sj-L6L-1 were assessed using a Kruskall-Wallis
one-way analysis of variance.
Results
Protein array screening with ASC-probes for antigen
identification
Screening of the 232 schistosome protein microarray with
antibodies obtained from lymph nodes (ASC-probes) of
S. japonicum challenged rats resulted in significant re-
cognition of 11 antigens (Table 1). Nine of these were
recognised by the lung ASC-probes, three by the skin ASC-
probes and one (tetraspanin-2; TSP-2) was recognised by
both skin and lung ASC-probes. Only 3 antigens were con-
sistently recognised by all four of the lung ASC-probes;
these were the novel hypothetical protein AY815838, and
the known vaccine candidates TSP-2 and 21.7 kDa antigen
(Sj21.7). Other known molecules that were recognised
by the ASC-probes included 22.6 kDa antigen (Sj22.6),
S. mansoni filamin, dynein light chain 1 (DLC1), S. mansoni
tetraspanin-3, and the 29 kDa antigen (Sj29). Because the
amount of protein in each spot is not standardised due to
the cell-free expression system used [29,30], it should be
noted, however, that the degree of antibody binding to pro-
teins on the array does not necessarily indicate antigenicity.
Therefore, even weakly recognised antigens, such as Ly-6-
like protein 1 (Sj-L6L-1), which was only recognised by one
skin and lung ASC-probe sample, may also be considered
as relevant antigenic targets.
To select antigens for further characterisation, each of
the 11 sequences were investigated as to its novelty, its po-
tential for up-regulated larval expression, and predicted
exposure to the host’s immune system (indicated by the
presence of a signal peptide and/or transmembrane
domain). Five of the eleven proteins identified were novel
and recognised by lung ASC probes, and three of these
Table 1 S. japonicum protein array antigen recognition by rat ASC-probes
Recognition* by ASC-probes
Name Accession no. Skin (No.) Lung (No.) NovelΔ Expression profile# SignalP† TM∞
Tetraspanin-2 (SjTSP2) EF553319.1 ++ (3) +++ (4) No S No Yes
Hypothetical protein AY815838 + (1) +++ (4) Yes S Yes Yes
22.6 kDa antigen (Sj22.6) L08198 - (0) +++ (3) No S, A No Yes
Calponin-like AY813467 - (0) ++ (3) Yes S No No
Filamin XM_002571418 - (0) +++ (2) No C, S, A, Sp No Yes
21.7 kDa antigen (Sj21.7) AF048759 + (1) ++ (4) No S,A No No
Dynein light chain AF072327.1 - (0) ++ (2) No E, S No No
Zinc finger protein AY223099 ++ (1) + (2) Yes E, A No No
Ly6-like (Sj-L6L-1) AY816003 + (1) ++ (1) Yes S Yes Yes
Tetraspanin-3 SmTSP3 (S. mansoni) CABG01000023 + (3) - (0) Yes ^ No Yes
29 kDa antigen (Sj29) DQ873812.1 + (3) + (1) No S, A Yes Yes
*Recognition level score: the average signal intensity of the individual(s) which were greater than the mean + 2SD of control serum. High (+++) >10000 SI; Moderate
(++) 500–9999 SI; Low (+) 0–499 SI; Negative (−) 0 SI. Number of ASC-probe samples (out of four) that recognised each antigen is indicated in parentheses. ΔNovel:
defined as not having been tested as a vaccine candidate against S. japonicum and limited characterisation. #Expression profile: The stage(s) with the highest expression
is indicated, based on EST Profile Viewer, UniGene, NCBI: cercariae (C), schistosomula (S), adult worm (A), egg (E), sporocyst (Sp). †Signal peptide determined by SignalP −4.1
(www.cbs.dtu.dk/services/SignalP/). ∞Transmembrane prediction by TMpred (www.ch.embnet.org/software/TMPRED_form.html) ^Data on sequence not present in
UniGene. Three antigens possessing ideal characteristics as novel vaccine candidates are highlighted in bold.
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schistosomula stage. Two of the novel antigens, AY815838
and Sj-L6L-1, were predicted to have signal peptides and
transmembrane domains. The third novel antigen identi-
fied, calponin-like protein, had no predicted host-exposed
features.
The AY815838 protein is currently unknown, but has
limited amino acid sequence identity to two surface anti-
gens of S. mansoni: Sm25 (accession #AAA29943; 34%
identity) and Sm13 (accession #AAC25419.1; 30% iden-
tity). Sj-L6L-1 has significant homology to a S. mansoni
antigen that was briefly investigated in a DNA vaccine
study [31] and recently designated Sm-CD59.2 [32]. Finally
calponin-like protein has a predicted size of 27 kDa and
has some homology with a 38 kDa S. japonicum calponinFigure 1 Developmental expression of novel S. japonicum antigens re
AY815838 (A), calponin-like protein (B) and Sj-L6L-1 (C) in developmental s
Stages examined were cercariae (C), 2 day- (2d) and 3 day-old (3d) schistos
(E). Normalized fold expression of the genes relative to the expression in cehomologue (accession #AAD11976; 63% identity) pre-
viously investigated [33].
Developmental expression analysis of novel antigens
The developmental expression of the three novel antigen
transcripts was investigated by qPCR (Figure 1). The
AY815838 transcript was most highly expressed in the
2 day schistosomula, elevated to 65 times the cercarial ex-
pression, which then reduced to 5 and 10 times cercarial
expression levels in 3-day schistosomula and adult pairs,
respectively. The calponin-like protein showed a steady in-
crease in expression throughout the development of the
intravascular stages, peaking in the adult worms at 41
times the cercarial expression. Finally, Sj-L6L-1 was very
highly expressed in the developing schistosomula; thecognised by lymph node-derived ASC-probes. Expression levels of
tages of S. japonicum were determined by quantitative real-time PCR.
omula (S), adult pairs (A), adult males (M), adult females (F) and eggs
rcariae is presented, and bars represent standard error of the mean.
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larvae had 23 and 27 times the cercarial expression re-
spectively, whereas adult males had just a 3-fold -increase
in transcript level. For all three genes, expression in adult
worms was predominantly, or restricted to, the males.
These data suggested AY815838 and Sj-L6L-1 were
promising novel targets with predominant larval expression.
The larval expression of Sj-L6L-1 was particularly convin-
cing since there was strong agreement in transcript levels in
samples from both in vitro and in vivo-generated larvae
(2- and 3-day schistosomula, respectively). AY815838 was
identified in a previous screening of the microarray and isFigure 2 Sequence and predicted structure of mature Sj-L6L-1. A: The
from S. mansoni (Sm-CD59.2) and S. haematobium (Sh-L6L-1) and compared w
Hs-CD59). The N-terminal signal peptide and the C-terminal propeptide are h
highlighted in red. The predicted omega site (GPI-anchor site) is highlighted i
black triangles. B: The predicted structure of mature Sj-L6L-1 was modelled ba
the typical three-finger fold common to Ly-6 family proteins. Each finger is lab
sequence has the predicted disulfide bonding pattern, also characteristic of th
are shown and numbered in magenta, with those predicted by the in silico a
lines.being currently investigated (P. Driguez and D. McManus,
personal communication); therefore Sj-L6L-1 was selected
for further detailed characterisation.
Sequence analysis of Sj-L6L-1
Database searching revealed Sj-L6L-1 has similarity with
the Lymphocyte Antigen 6 (Ly-6) family of proteins,
present in many eukaryotic species (Figure 2). The mem-
brane-anchored members of this family share several
features: a predicted N-terminal signal peptide, a glycosyl-
phosphatidylinositol (GPI)-anchor omega site where the
C-terminal propeptide is cleaved off in the mature protein,Sj-L6L-1 sequence aligned with the highly similar orthologous sequences
ith Ly-6 family proteins from mice (Mm-Ly-6D) and humans (Hs-E48 and
ighlighted in grey, while structurally important cysteine residues are
n blue. The predicted mature Sj-L6L-1 sequence is indicated within the
sed on a Phyre2 structure homology search, revealing a structure with
elled with green roman numerals. C: The mature Sj-L6L-1 amino acid
is family, including the GPI-anchor at the C-terminus. The disulfide bonds
nalysis depicted by solid lines and those manually inferred by dotted
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8–10 conserved cysteine residues [34].
Highly related orthologues to Sj-L6L-1 were found in
S. mansoni (SmCD59.2; accession number XP_002570561)
and S. haematobium (Sh-L6L-1; B_00489), which have 78
and 79% amino acid identity, respectively. All three have
most of the classical Ly-6 family features: predicted signal
peptides, GPI-anchor omega site, and ten cysteines in
the mature region (eight of these align with conserved
mammalian residues but two are in differing positions)
(Figure 2A). However, domain searching using the amino
acid sequence did not predict the presence of an LU do-
main in these schistosome orthologues, most likely due to
the altered positions of the 3rd and 4th cysteines (see
Figure 2A). These altered cysteines were common in all
trematode orthologues examined (Figure 2A and data not
shown). The S. mansoni orthologue, SmCD59.2, was re-
cently described along with other members of its family by
Farias et al. [32]. This family was referred to as CD59-like
proteins because they have some similarity with the mam-
malian Ly-6 family member, CD59. However, since the
schistosome proteins more closely resemble the family of
Ly-6 proteins rather than one particular member, we
propose to describe them as ‘Ly-6-like’ proteins. S. japo-
nicum also has several orthologous sequences to
Sj-L6L-1, although the closest Sj-L6L-2 (accession
number AAW26563.1), has only 38% identity.
The full pre-protein sequence of Sj-L6L-1 is predicted
to be 14.1 kDa, while the mature protein after the signal
peptide and propeptide are cleaved is estimated to be
8.9 kDa. However, the addition of the GPI anchor is esti-
mated to add a similar amount to the cleaved propeptide
[35], so the native form would be approximately 12 kDa.
Other parasitic trematode sequences with low identity
(31-34%) to Sj-L6L-1 were identified in F. hepatica
(Fh_Contig6273), F. gigantica (Contig25430), C.sinensis
(CS1_c757) and O. viverrini (OV1_c8524). The closest
mammalian orthologues are the mouse Ly-6D (also known
as ThB; 28% identity; accession # EDL29445), the human
E48 protein (32% identity; accession # CAA73189).
Human CD59 in contrast has 25% identity (accession #
CAG46523).
Despite not having a traditional LU domain by se-
quence searching, structural homology searching of the
mature Sj-L6L-1 sequence predicted structural similarity
with Ly-6 proteins. The highest scoring template follo-
wing the Phyre2 server search was the Ly-6 protein
Lynx1, with 98.3% confidence. As shown in Figure 2B, in
silico modelling predicted a three-fingered structure
which is common to Ly-6-like proteins [36]. This struc-
ture was predicted to contain 3 disulfide bonds, num-
bered 1, 4 and 5 in Figure 2B and C. Disulfide bonds 2
and 3 depicted in Figure 2 were manually added since
this is the same pattern seen in other Ly-6 proteins suchas human Lynx1 [37] and CD59 [38,39], and because the
residues are in close proximity in the model (Figure 2B).
Recombinant Sj-L6L-1 is in the native antigenic
conformation
Recombinant Sj-L6L-1 was produced fused to thioredoxin
(Trx) as a solubility tag, and induction with arabinose
caused a significant expression of a soluble protein band
at approximately 27 kDa as observed by reducing SDS-
PAGE (Figure 3). This was purified by the 6His tag using a
nickel column. The protein band was excised and the
sequence confirmed by LC-MS/MS using a HCT ULTRA
ion trap mass spectrometer (Bruker Daltonics; Monash
Biomedical Proteomics Facility). Under non-reducing
conditions the protein had a molecular weight of 25 kDa
(Figure 3A, lane 4). This reduction in size was likely due
to a change in the Sj-L6L-1 portion of the fusion protein,
since reducing or non-reducing conditions had no effect
on the size of rTrx which remained at 16 kDa (lanes 2 and
3). Finally, immunoblotting revealed rSj-L6L-1 was recog-
nised by the rat lung ASC-probes from infected rats, but
only in the non-reduced form (Figure 3A, lane 6). This in-
dicated that the recombinant protein shares confor-
mational epitopes with the native protein, and these are
abolished by treating with reducing agent, presumably by
disrupting the disulfide bonds between the structurally-
important cysteines.
It was also noted that there was a ladder effect with rSj-
L6L-1 in the non-reduced sample (Figure 3A, lane 4).
These corresponded to multimers of the protein, visible at
50 kDa (dimer) and 75 kDa (trimer) and then increasing
masses that were not distinguishable. In the reduced sam-
ple (lane 5) only an additional 55 kDa band was present,
likely to be a dimer of the reduced form. These bands also
reacted with an anti-His tag antibody (data not shown),
indicating that they are aggregates of rSj-L6L-1, but none
of the multimers were recognised by the lung ASC-probes
compared to the 25 kDa monomer.
Recombinant Sj-L6L-1 is recognised by the local lung
antibody response in rats
Since lung ASC-probes were found to recognise non-
reduced rSj-L6L-1 (Figure 3A), an ELISA was used to in-
vestigate the binding of the different rat ASC-probe
samples to rSj-L6L-1 (Figure 3B). To account for some
background binding to the fusion tag alone, the data are
presented as relative binding (RB) of rSj-L6L-1 to rTrx,
where RB > 1 means the sample bound to rSj-L6L-1
greater than the rTrx control. Figure 3B illustrates that
the non-infected (NI) rat sera had no recognition of rSj-
L6L-1 with a mean of 0.8 RB. The only sample type to
have a statistically significant recognition of rSj-L6L-1
was the lung ASC-probes, with a mean of 4.8 RB
(p = 0.039). The skin ASC-probes had some slight
Figure 3 Recombinant Sj-L6L-1 (rSj-L6L-1) contains conformational epitopes. A: The purified fusion protein of rSj-L6L-1 with thioredoxin (Trx),
or rTrx alone, were analysed by SDS-PAGE under non-reducing conditions (lanes 2, 4, 6) or reducing conditions with dithiothreitol (DTT; lanes 3, 5, 7).
DTT had no effect on rTrx but slightly increased the size of rSj-L6L-1. Reduced and non-reduced rSj-L6L-1 was transferred to a nitrocellulose membrane
and probed with lung-LN ASC-probes (lanes 6–7). B: rSj-L6L-1 ELISA with rat ASC-probes obtained from skin-, lung- or liver-LN or spleen compared
with non-infected (NI) rat serum. Relative binding to rSj-L6L-1 is the ratio of the rSj-L6L-1 optical density to that of the fusion partner, rTrx, alone. Bars
represent the mean ± standard error.
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significantly higher than the other groups.
Native Sj-L6L-1 is present in tegument extract
Schistosome extracts probed with antiserum to rSj-L6L-1
recognised a band of approximately 12 kDa in all develop-
mental stages examined (Figure 4A), with an additional
band of approximately 10 kDa observed only in the schis-
tosomula. Neither of these were recognised by antiserum
to rTrx (data not shown). The 12 kDa Sj-L6L-1 band was
similar in intensity comparing schistosomula and adult
worm pairs, and it was clear that the protein is more
abundant in male worms than females. Due to the scarcity
of larval material and the difficulty in removing the larval
tegument [40], tegument extracts were generated from
adult worms only. The same 12 kDa band was seen in the
worm tegument and insoluble fractions (Figure 4B), but
not in the aqueous-soluble fraction. This indicates rSj-Figure 4 Detection of native Sj-L6L-1 in S. japonicum extracts. A: Prote
worm pairs (A), or separated male (M) or female (F) worms were analysed b
immunoblotting (lanes 7–11) with antisera to rSj-L6L-1. Molecular weight (M
into tegument (teg), aqueous-soluble (sol) and -insoluble (ins) worm fractioL6L-1 is located in the tegument and is membrane-
associated.
Discussion
In this study, a novel post-genomic technique, a protein
microarray, was employed to identify schistosome vaccine
candidates. To focus on the identification of antigens im-
portant in the vulnerable larval stages, rat lymph node
antibody samples (ASC-probes) generated previously from
the sites of larval infection [17], the skin and lungs, were
used to screen the arrays. The combination of these two
‘immunomic’ technologies – the protein microarray, pro-
viding multiple antigen binding data, and the ASC-probe
samples, which provide tissue-specific reactivity, resulted
in a list of targets which may contribute to a vaccine tar-
geting the migrating larvae [18]. Several novel and also
known vaccine candidates were recognised; one of these,
named Sj-L6L-1, was further characterised and has severalin extracts from S. japonicum cercariae (C), schistosomula (S), adult
y SDS-PAGE and stained with coomassie (lanes 2–6) or subjected to
W) markers are shown in lane 1. B: Adult worms were fractionated
ns, and analysed by immunoblotting with antisera to rSj-L6L-1.
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relevant to the developing larvae.
The known targets included TSP-2, a tegumental anti-
gen for which the homologue in S. mansoni is currently
under further development as a vaccine candidate [2]. The
present study suggests that TSP-2 is exposed to the host’s
immune system in both the skin and lung sites during rat
S. japonicum infection, since it was strongly recognised by
skin and lung ASC-probes. Other known vaccine candi-
dates recognised by the lung ASC-probes were: Sj22.6 and
Sj21.7, both tegument-associated proteins from the TAL
protein family [41]; S. mansoni filamin, a large structural
protein shown to confer some protection in a mouse
model [42]; and DLC1 which has been found associated
with the worm surface [43,44]. In addition, two further
molecules, S. mansoni TSP-3 and Sj29, were recognised
by the skin ASC-probes, indicating that they are antigenic
predominantly during skin invasion. These are both pur-
ported to be surface molecules and Sj29 has been investi-
gated as a vaccine candidate [45]. Gobert et al. [46] found
that in S. mansoni, the genes encoding both proteins had
significantly up-regulated transcript expression after trans-
formation from cercariae to larvae, and notably Sm29 (the
homologue of Sj29) had the highest expression in the
3 hour schistosomulum, the stage which develops shortly
after skin penetration.
A major criterion used in the present study to select
novel antigens for further characterisation was increased
larval expression. Initially, the NCBI EST database was
used as a preliminary measure of developmental expres-
sion. This indicated that only one of the four novel tar-
gets was not up-regulated in schistosomula, the zinc
finger protein (AY223099). This antigen also lacked a
signal peptide and transmembrane domain, and is likely
to be an intracellular protein and therefore may only be
exposed to the host’s immune system during parasite
damage. The developmental expression of the remaining
three antigens was confirmed by qPCR, and both
AY815838 and Sj-L6L-1 showed high larval gene expres-
sion relative to cercariae. AY815838 was dramatically
up-regulated in the 2 day in vitro-cultured, but not the
3 day in vivo lung-isolated, schistosomula. This high ex-
pression in the in vitro larvae could indicate an early
high expression that is then reduced after 3 days, or
could be an artefact of in vitro culture. Sj-L6L-1, how-
ever, showed a more consistent larval expression, with
similar up-regulated levels in the 2 day and 3 day larvae
compared with other stages.
Based on these analyses, Sj-L6L-1 was selected for fur-
ther characterisation and was produced in recombinant
form. The E. coli-expressed rSj-L6L-1 fusion protein was
recognised by the lung ASC-probes indicating that it
was at least partly in the correct antigenic conformation.
By treating with reducing agent, the protein structurewas altered sufficiently to ablate recognition by these
antibodies, indicating that the schistosomiasis-induced
antibodies recognised only conformational epitopes on
the recombinant protein The disulfide bonds in Ly-6
proteins are known to be important for their structural
conformation, stabilising the typical three-finger motif;
for example, when CD59 is treated with reducing agent
it loses its ability to inhibit the complement system [39].
The Sj-L6L-1 protein was identified in all life-stages ex-
amined. No increase in protein expression was seen in the
schistosomula despite the significant increase in transcrip-
tion. However, an additional band was recognised in the
schistosomula and this could represent either an imma-
ture form of the protein or another variation unique to
this developmental stage. The Sj-L6L-1 protein was also
detected in the tegument extract from adult S. japonicum
worms, and the same band was found in the insoluble
fraction from the ‘denuded’ adult worms. This indicates
that Sj-L6L-1 is at least associated with the outer tegu-
ment, and is highly likely to be on the external surface as
is the case for its homologue in S. mansoni [47]. It also
suggests that the protein is attached to the plasma mem-
brane, since it was only detected in the insoluble fraction;
hence, it is unlikely to be secreted like some Ly-6 proteins.
Another important observation was that local antibodies
obtained from rat lymph nodes draining the lung, the site
of larval killing, were specific for rSj-L6L-1. No specific
antibody was evident against the protein in lymph node
samples obtained from the liver, where more mature
worms reside, despite the fact that male adults do produce
the protein. This suggests that Sj-L6L-1 is uniquely ex-
posed during larval development and not in adult worms.
It is possible that this occurs after the transformation of
the schistosomula from cercariae, when the larvae rapidly
synthesise the new tegument [48] and before they acquire
host proteins which mask their own antigens [9].
While Sj-L6L-1 is novel for S. japonicum, the closest
homologue in S. mansoni (SmCD59.2) and its family have
been recently characterised [32]. Previously, two of the
members of this family were identified in the adult S.
mansoni worm tegument using proteomics [47]. Farias
et al. [31] analysing the S. mansoni transcriptome for
genes up-regulated from the cercariae to the schistoso-
mula, identified SmCD59.2 (which they refer to as ‘dif 5’)
and performed a limited DNA vaccine trial which resulted
in a slight (but non-significant) reduction (22%) in worm
burden.
The Ly-6 family of proteins was originally described in
mice, but Ly-6-like proteins have since been found in
many animal species from C. elegans to humans and
comprise the Ly-6 super gene family [49]. These are
broadly grouped together based on the presence of 8–10
conserved cysteines which comprise the LU domain
[34]. These conserved cysteines create 4–5 disulfide
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common to the related snake venom toxins [36]. Since
Sj-L6L-1 is related to this family by containing most of
these features, it is referred to here as Ly-6-like and part
of the Ly-6 super family. The Ly-6 family members and
Ly-6-like proteins appear to have extremely diverse
roles, although their precise functions are as yet unclear
[50]. This family of proteins also exhibit limited se-
quence identity between members [49], which makes
assigning a putative function to Sj-L6L-1 difficult. They
are generally thought to participate in development, cell
adhesion, and cell signalling, although how the latter
occurs is still unknown [49].
Conclusions
In summary, a novel protein microarray was combined
with a tissue-specific antibody source to investigate the
immunome of migrating S. japonicum larvae and to iden-
tify novel antigens expressed by the schistosomula stage,
which is generally considered the likely target of an anti-
schistosome vaccine. Several novel and known proteins
were found to be antigenic in the regions of larval migra-
tion and could form part of a multivalent vaccine speci-
fically targeting the schistosomula. Although these targets
were identified using rat samples, their vaccine efficacy
should ideally be tested in a final host such as the water
buffalo to account for differences in immune mechanisms
between species [51]. Of the identified molecules, a novel
S. japonicum protein, Sj-L6L-1, was characterised and
found to be antigenic in the larval stage and present, but
not antigenic, in the worm tegument, and may provide a
valuable vaccine candidate against schistosomiasis.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
PD probed the microarrays, HM & PD analysed the microarray data and
isolated parasite samples, HM synthesised and characterised Sj-L6L-1, and
drafted the manuscript. HM, PD, EM, DP and DPM interpreted results and
edited, drafted and approved the final manuscript.
Acknowledgements
We wish to acknowledge Mary Duke for her S. japonicum infection and
animal handling expertise, and financial support from the National Health
and Medical Research Council of Australia and the Australian Research
Council Centre of Excellence in Structural & Functional Microbial Genomics.
HM was supported by a NHMRC postgraduate scholarship (number 607203).
DPM is a NHMRC Senior Principal Research Fellow.
Author details
1Department of Microbiology and Immunology, The University of Melbourne,
at the Peter Doherty Institute for Infection and Immunity, Melbourne,
Victoria, Australia. 2Molecular Parasitology Laboratory, QIMR Berghofer
Medical Research Institute, Brisbane, Queensland, Australia. 3School of
Applied Sciences & Engineering, Federation University, Churchill, Victoria,
Australia. 4Department of Microbiology, School of Biomedical Sciences,
Monash University, Melbourne, Victoria, Australia.
Received: 26 April 2014 Accepted: 20 June 2014
Published: 25 June 2014References
1. McManus DP, Loukas A: Current status of vaccines for schistosomiasis.
Clin Microbiol Rev 2008, 21(1):225–242.
2. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A: Developing
vaccines to combat hookworm infection and intestinal schistosomiasis.
Nat Rev Microbiol 2010, 8(11):814–826.
3. Bergquist R, Utzinger J, McManus DP: Trick or treat: the role of vaccines in
integrated schistosomiasis control. PLoS Negl Trop Dis 2008, 2(6):e244.
4. Bickle QD: Radiation-attenuated schistosome vaccination - a brief historical
perspective. Parasitology 2009, 136(12):1621–1632.
5. Wilson RA, Coulson PS: Schistosome vaccines: a critical appraisal. Mem Inst
Oswaldo Cruz 2006, 101(Suppl 1):13–20.
6. Pearce EJ, MacDonald AS: The immunobiology of schistosomiasis. Nat Rev
Immunol 2002, 2(7):499–511.
7. McManus DP, Gray DJ, Li Y, Feng Z, Williams GM, Stewart D, Rey-Ladino J,
Ross AG: Schistosomiasis in the People’s Republic of China: the era of the
three gorges dam. Clin Microbiol Rev 2010, 23(2):442–466.
8. Gryseels B, Polman K, Clerinx J, Kestens L: Human schistosomiasis. Lancet
2006, 368(9541):1106–1118.
9. Skelly PJ, Wilson A: Making sense of the schistosome surface. Adv Parasitol
2006, 63:185–284.
10. Harris AR, Russell RJ, Charters AD: A review of schistosomiasis in
immigrants in Western Australia, demonstrating the unusual longevity of
Schistosoma mansoni. Trans R Soc Trop Med Hyg 1984, 78(3):385–388.
11. McWilliam HEG, Driguez P, Piedrafita D, McManus DP, Meeusen ENT: Novel
immunomic technologies for schistosome vaccine development. Parasite
Immunol 2012, 34(5):276–284.
12. Zhou Y, Zheng H, Liu F, Hu W, Wang ZQ, Gang L, Ren S: The schistosoma
japonicum genome reveals features of host-parasite interplay. Nature
2009, 460(7253):345–351.
13. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama
ST, Al-Lazikani B, Andrade LF, Ashton PD, Aslett MA, Bartholomeu DC, Blandin G,
Caffrey CR, Coghlan A, Coulson R, Day TA, Delcher A, DeMarco R, Djikeng A, Eyre
T, Gamble JA, Ghedin E, Gu Y, Hertz-Fowler C, Hirai H, Hirai Y, Houston R, Ivens A,
Johnston DA, et al: The genome of the blood fluke Schistosoma mansoni.
Nature 2009, 460(7253):352–358.
14. Young ND, Jex AR, Li B, Liu S, Yang L, Xiong Z, Li Y, Cantacessi C, Hall RS, Xu
X, Chen F, Wu X, Zerlotini A, Oliveira G, Hofmann A, Zhang G, Fang X, Kang
Y, Campbell BE, Loukas A, Ranganathan S, Rollinson D, Rinaldi G, Brindley PJ,
Yang H, Wang J, Gasser RB: Whole-genome sequence of schistosoma
haematobium. Nat Genet 2012, 44(2):221–225.
15. Walker A: Insights into the functional biology of schistosomes. Parasit
Vectors 2011, 4(1):203.
16. Driguez P, Doolan DL, Loukas A, Felgner PL, McManus DP: Schistosomiasis
vaccine discovery using immunomics. Parasit Vectors 2010, 3:4.
17. McWilliam HE, Driguez P, Piedrafita D, Maupin KA, Haab BB, McManus DP,
Meeusen EN: The developing schistosome worms elicit distinct immune
responses in different tissue regions. Immunol Cell Biol 2013, 91(7):477–485.
18. Capron M, Capron A: Rats, mice and men - models for immune effector
mechanisms against schistosomiasis. Parasitol Today 1986, 2(3):69–75.
19. Hu Y, Lu W, Shen Y, Xu Y, Yuan Z, Zhang C, Wu J, Ni Y, Liu S, Cao J:
Immune changes of schistosoma japonicum infections in various rodent
disease models. Exp Parasitol 2012, 131(2):180–189.
20. Han H, Peng J, Hong Y, Zhang M, Han Y, Fu Z, Shi Y, Xu J, Tao J, Lin J:
Comparison of the differential expression miRNAs in wistar rats before
and 10 days after S.Japonicum infection. Parasit Vectors 2013, 6(1):120.
21. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M: Variance
stabilization applied to microarray data calibration and to the
quantification of differential expression. Bioinformatics 2002,
18(Suppl 1):S96–S104.
22. Sundaresh S, Doolan DL, Hirst S, Mu Y, Unal B, Davies DH, Felgner PL,
Baldi P: Identification of humoral immune responses in protein
microarrays using DNA microarray data analysis techniques.
Bioinformatics 2006, 22(14):1760–1766.
23. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL, Baldi P,
Felgner PL, Doolan DL: Sterile protective immunity to malaria is
associated with a panel of novel P. falciparum antigens. Mol Cell
Proteomics 2011, 10(9):M111. 007948.
24. Gobert GN, Moertel L, Brindley PJ, McManus DP: Developmental gene
expression profiles of the human pathogen schistosoma japonicum.
BMC Genomics 2009, 10:128.
McWilliam et al. Parasites & Vectors 2014, 7:290 Page 11 of 11
http://www.parasitesandvectors.com/content/7/1/29025. Liu S, Cai P, Hou N, Piao X, Wang H, Hung T, Chen Q: Genome-wide
identification and characterization of a panel of house-keeping genes in
schistosoma japonicum. Mol Biochem Parasitol 2012, 182(1–2):75–82.
26. Kelley LA, Sternberg MJ: Protein structure prediction on the web: a case
study using the phyre server. Nat Protoc 2009, 4(3):363–371.
27. Roberts SM, MacGregor AN, Vojvodic M, Wells E, Crabtree JE, Wilson RA:
Tegument surface membranes of adult schistosoma mansoni:
development of a method for their isolation. Mol Biochem Parasitol 1983,
9(2):105–127.
28. Mulvenna J, Moertel L, Jones MK, Nawaratna S, Lovas EM, Gobert GN,
Colgrave M, Jones A, Loukas A, McManus DP: Exposed proteins of the
schistosoma japonicum tegument. Int J Parasitol 2010, 40(5):543–554.
29. Doolan DL: Plasmodium immunomics. Int J Parasitol 2011, 41(1):3–20.
30. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, Romero KM,
Nguyen TT, Kalantari-Dehaghi M, Crotty S, Baldi P, Villarreal LP, Felgner PL:
Profiling the humoral immune response to infection by using proteome
microarrays: high-throughput vaccine and diagnostic antigen discovery.
Proc Natl Acad Sci U S A 2005, 102(3):547–552.
31. Farias LP, Tararam CA, Miyasato PA, Nishiyama MY Jr, Oliveira KC, Kawano T,
Verjovski-Almeida S, Leite LC: Screening the schistosoma mansoni
transcriptome for genes differentially expressed in the schistosomulum
stage in search for vaccine candidates. Parasitol Res 2011, 108(1):123–135.
32. Farias LP, Krautz-Peterson G, Tararam CA, Araujo-Montoya BO, Fraga TR,
Rofatto HK, Silva-Jr FP, Isaac L, Da’dara AA, Wilson RA, Shoemaker CB, Leite
LCC: On the three-finger protein domain fold and CD59-like proteins in
Schistosoma mansoni. PLoS Negl Trop Dis 2013, 7(10):e2482.
33. Yang W, Zheng YZ, Jones MK, McManus DP: Molecular characterization of
a calponin-like protein from schistosoma japonicum. Mol Biochem
Parasitol 1999, 98(2):225–237.
34. Stroncek DF, Caruccio L, Bettinotti M: CD177: a member of the Ly-6 gene
superfamily involved with neutrophil proliferation and polycythemia
Vera. J Transl Med 2004, 2(1):8.
35. Patel BN, David S: A novel glycosylphosphatidylinositol-anchored form of
ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem 1997,
272(32):20185–20190.
36. Fry BG, Wuster W, Kini RM, Brusic V, Khan A, Venkataraman D, Rooney AP:
Molecular evolution and phylogeny of elapid snake venom three-finger
toxins. J Mol Evol 2003, 57(1):110–129.
37. Miwa JM, Ibanez-Tallon I, Crabtree GW, Sanchez R, Sali A, Role LW, Heintz N:
Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine
receptors in the mammalian CNS. Neuron 1999, 23(1):105–114.
38. Sugita Y, Nakano Y, Oda E, Noda K, Tobe T, Miura NH, Tomita M:
Determination of carboxyl-terminal residue and disulfide bonds of
MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane
protein. J Biochem 1993, 114(4):473–477.
39. Morgan BP, Tomlinson S: Structure-Function Relationships in CD59. In
Structural Biology of the Complement System. Edited by Lambris JD, Morikis
D. Boca Raton: Taylor & Francis; 2005:251–264.
40. Wilson RA: Proteomics at the schistosome-mammalian host interface:
any prospects for diagnostics or vaccines? Parasitology 2012,
139(9):1178–1194.
41. Fitzsimmons CM, Jones FM, Stearn A, Chalmers IW, Hoffmann KF,
Wawrzyniak J, Wilson S, Kabatereine NB, Dunne DW: The Schistosoma
mansoni tegumental-allergen-like (TAL) protein family: influence of
developmental expression on human IgE responses. PLoS Negl Trop Dis
2012, 6(4):e1593.
42. Cook RM, Carvalho-Queiroz C, Wilding G, LoVerde PT: Nucleic acid vaccination
with schistosoma mansoni antioxidant enzyme cytosolic superoxide
dismutase and the structural protein filamin confers protection against the
adult worm stage. Infect Immun 2004, 72(10):6112–6124.
43. Yang W, Jones MK, Fan J, Hughes-Stamm SR, McManus DP: Characterisation
of a family of schistosoma japonicum proteins related to dynein light
chains. Biochim Biophys Acta 1999, 1432(1):13–26.
44. Zhang LH, McManus DP, Sunderland P, Lu XM, Ye JJ, Loukas A, Jones MK:
The cellular distribution and stage-specific expression of two dynein
light chains from the human blood fluke schistosoma japonicum. Int J
Biochem Cell Biol 2005, 37(7):1511–1524.
45. Balloul JM, Grzych JM, Pierce RJ, Capron A: A purified 28,000 Dalton
protein from schistosoma mansoni adult worms protects rats and mice
against experimental schistosomiasis. J Immunol 1987, 138(10):3448–3453.46. Gobert GN, Tran MH, Moertel L, Mulvenna J, Jones MK, McManus DP,
Loukas A: Transcriptional changes in schistosoma mansoni during early
schistosomula development and in the presence of erythrocytes. PLoS
Negl Trop Dis 2010, 4(2):e600.
47. Castro-Borges W, Dowle A, Curwen RS, Thomas-Oates J, Wilson RA: Enzymatic
shaving of the tegument surface of live schistosomes for proteomic
analysis: a rational approach to select vaccine candidates. PLoS Negl Trop Dis
2011, 5(3):e993.
48. Hockley DJ, McLaren DJ: Schistosoma mansoni: changes in the outer
membrane of the tegument during development from cercaria to adult
worm. Int J Parasitol 1973, 3(1):13–20.
49. Bamezai A: Mouse Ly-6 proteins and their extended family: markers of
cell differentiation and regulators of cell signaling. Arch Immunol Ther Exp
(Warsz) 2004, 52(4):255–266.
50. Mallya M, Campbell RD, Aguado B: Characterization of the five novel Ly-6
superfamily members encoded in the MHC, and detection of cells
expressing their potential ligands. Protein Sci 2006, 15(10):2244–2256.
51. McWilliam HEG, Piedrafita D, Li Y, Zheng M, He Y, Yu X, McManus DP,
Meeusen ENT: Local immune responses of the Chinese water buffalo,
bubalus bubalis, against schistosoma japonicum larvae: crucial insights for
vaccine design. PLoS Negl Trop Dis 2013, 7(9):e2460.
doi:10.1186/1756-3305-7-290
Cite this article as: McWilliam et al.: Discovery of novel Schistosoma
japonicum antigens using a targeted protein microarray approach.
Parasites & Vectors 2014 7:290.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
